Multi-Center Phase II Clinical Trial on Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinoma after Failure of Treatment with 1st-Line TKI Therapy.

Trial Profile

Multi-Center Phase II Clinical Trial on Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinoma after Failure of Treatment with 1st-Line TKI Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 01 Feb 2014 Results presented at the 2014 Genitourinary Cancers Symposium.
    • 17 Jan 2013 Planned end date added (11 Jan 2015) as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top